Katakura Industries (3001) Q2 2025 earnings summary

Executive summary

• Net sales for the first half of FY2025 rose 5.6% year-over-year to ¥20,755 million, driven by strong Machinery segment performance despite a decline in Pharmaceuticals.

• Operating income surged 49.6% to ¥3,156 million, exceeding forecasts, mainly due to cost reductions in Pharmaceuticals and gains from asset sales.

• Net income attributable to shareholders nearly doubled to ¥3,538 million, aided by extraordinary income from asset sales.

• All major business segments except Pharmaceuticals posted revenue growth; Machinery saw the largest increase.

• Extraordinary income surged due to asset sales, while impairment losses were eliminated compared to last year.

Financial highlights

• Net sales: ¥20,755M (up ¥1,104M YoY); Operating income: ¥3,156M (up ¥1,046M YoY); Net income: ¥3,538M (up ¥1,698M YoY).

• Gross profit increased to ¥13,229 million from ¥12,134 million YoY.

• EPS for the half-year was ¥110.26, compared to ¥55.76 in the prior year.

• Extraordinary income: ¥1,250M from asset sales; no extraordinary loss this period.

• Cash and cash equivalents at period end: ¥10,786M.

Outlook and guidance

• Full-year 2025 forecast revised upward: Net sales ¥40,700M, Operating income ¥5,000M, Net income ¥4,900M.

• EPS guidance increased to ¥153.65 for the full year.

• Upward revision reflects strong first-half results, lower R&D in Pharmaceuticals, cost declines in Machinery, and extraordinary income from asset sales.